NCT03485248

Brief Summary

Administration of antiretroviral therapy has brought benefits for infective human immunodeficiency virus-1 (HIV-1)-patients, reducing the number of AIDS-related morbidity and mortality. However, it is responsible for intensifying complications triggered by the chronic inflammatory state associated with virus infection, such as cardiovascular diseases. The current study evaluated effects of single dose (140mL) of Beetroot Juice (BJ) on macro and microvascular endothelial function in HIV-1-patients undergoing antiretroviral terapy, once BJ was shown to be effective in improving these physiological parameters in uninfected individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 18, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 13, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

April 2, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 28, 2018

Completed
Last Updated

April 29, 2019

Status Verified

April 1, 2019

Enrollment Period

10 months

First QC Date

March 13, 2018

Last Update Submit

April 25, 2019

Conditions

Keywords

HIV/AIDSArterial stiffnessFlow mediated-dilatationMuscle oxygenation parametersMicrocirculationDietary Nitrate

Outcome Measures

Primary Outcomes (2)

  • Skeletal Muscle Oxygenation

    Changes in skeletal muscle oxygenation in response to exercise will be evaluated by using a near-infrared spectroscopy device.

    Baseline and approximately after 150 minutes of beetroot juice consumption

  • Brachial artery flow-mediated dilatation

    The brachial artery flow-mediated dilation will be evaluated by using an ultrasound device.

    Baseline and approximately after 150 minutes of beetroot juice consumption

Secondary Outcomes (1)

  • Urinary nitrate concentrations

    Baseline and approximately 30, 90, and 150 minutes after beetroot juice consumption

Study Arms (2)

Beetroot juice

ACTIVE COMPARATOR

Beetroot Juice cotaining on average 9mmol of nitrate per dose

Dietary Supplement: Beetroot Juice

Placebo beet juice (Nitrate depleted)

PLACEBO COMPARATOR

Beetroot juice nitrate depleted

Dietary Supplement: Placebo

Interventions

Beetroot JuiceDIETARY_SUPPLEMENT

140ml of Beetroot Juice containing on avarege 9 mmol of nitrate

Beetroot juice
PlaceboDIETARY_SUPPLEMENT

140ml of Beetroot Juice (nitrate free)

Placebo beet juice (Nitrate depleted)

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • HIV infection for a period of 1 year or greater
  • Regular use of high-potency antiretroviral therapy for at least one year

You may not qualify if:

  • Individuals who are physically active
  • Individuals who are allergic to some component of beet
  • Individuals who use nutritional and / or pharmacological ergogenics
  • Individuals receiving antibiotics or who have osteomioarticular problems

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

DST / AIDS and Viral Hepatitis Program of Macaé

Macaé, Rio de Janeiro, Brazil

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double- Blind
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

March 13, 2018

First Posted

April 2, 2018

Study Start

October 18, 2017

Primary Completion

August 15, 2018

Study Completion

November 28, 2018

Last Updated

April 29, 2019

Record last verified: 2019-04

Locations